Krishna Institute of Medical Sciences (KIMS) investor relations material

Executive summary

• Q1 FY27 revenue reached INR 1,196 crore (₹11,795 Mn), up 36.1% year-on-year and 10.3% quarter-on-quarter, with strong operational growth and expanded capacity.

• EBITDA grew 20.1% year-on-year to INR 240 crore (₹2,398 Mn), with margin at 20.1%.

• PAT was INR 37 crore (₹374 Mn), down 56% year-on-year but up 13% quarter-on-quarter, impacted by higher costs and statutory changes.

• Significant expansion with 787 beds added in Kondapur and 208 beds in Palakkad during Q1 FY27.

• Unaudited standalone and consolidated financial results for Q1 FY27 were approved by the Board, with auditors expressing unmodified review opinions.

Financial highlights

• Consolidated revenue from operations at INR 1,180 crore (₹11,795 Mn), up 35.3% year-on-year and 9.8% quarter-on-quarter.

• EBITDA: ₹2,398 Mn (20.1% margin), up 20.1% YoY and 10.9% QoQ.

• PAT: ₹374 Mn, down 56% YoY but up 13% QoQ.

• ARPOB rose 9.7% YoY to ₹47,200; occupancy at 49%.

• Cash and cash equivalents stood at INR 505 crore as of June 30, 2026.

Outlook and guidance

• Focus on ramping up new hospitals, especially Kondapur and upcoming Thrissur unit, and expanding bed capacity with 1,300+ beds planned.

• Kerala cluster expected to stabilize at 20%-22% EBITDA margin over 2-3 years.

• Telangana cluster occupancy targeted to reach 70% in 3-4 years, with EBITDA margins of 30%-35%.

• Board approved raising up to Rs 6,000 million via convertible warrants to promoters, convertible within 18 months.

• Board approved advancing loans and guarantees up to Rs 650 crore to subsidiaries, subject to shareholder approval.